News

Results from the SELECT trial presented at the American Heart Association Scientific Sessions meeting suggest that the GLP-1 inhibitor may have a role in cardiovascular disease protection beyond weight loss and diabetes.

The Choosing Wisely campaign has helped with overscreening and overtreatment. Some experts say better management of end-of-life care and value-based payment would also help steer oncology away from care with poor cost-benefit ratios.

Otsuka American Pharmaceutical is tracking payer practices and attitudes about digital therapeutics with a series of four surveys.

Wayne B. Batchelor, M.D., Associate Director of Inova Heart and Vascular Institute, discusses the latest advancements in less invasive techniques for treating pulmonary regurgitation.

The evidence for active surveillance is stronger, but advances in imaging have improved the ability to distinguish between indolent and aggressive forms of prostate cancer.

Tirzepatide, with the brand name Zepbound, is expected to be available by the end of the year in six doses at a list price of $1,059.87, which is about 20% lower than semaglutide.

Briana Contreras, an editor with Managed Healthcare Executive, spoke with Harsha Rajasimha, MD, founder and executive chairman of IndoUSrare, in this month's episode of Tuning in to the C-Suite podcast. The conversation was about how the disparity in diversity and ethnicity in rare disease clinical trials in the U.S. has led to gaps in understanding diseases and conditions, jeopardizing universal health, and increasing the economic burden of healthcare.

Researchers at the University of California, San Francisco, report positive results from the No One Waits study.

One patient had complications that resulted in no light perception — effectively, blindness — in the the treated eye.

A ketogenic diet, which is low carbohydrates and rich in fat, is linked to successful in vitro fertilization in people with polycystic ovary syndrome.

Approximately one-third of the patients assigned to 16-week intervals of 8-mg formulation of Eylea changed to a 24-week interval during the second year of. the study, according results presented at the annual meeting of the American Academy of Ophthalmology. The PHOTON study enrolled people with diabetic macular edema.

Albert S. Khouri, M.D., a professor of ophthalmology at the Rutgers New Jersey Medical School, discusses teleophthalmology’s role in outreach efforts and improving ophthalmic care in the emergency room.

Albert S. Khouri, M.D., says ophthalmic care lends itself to telehealth because it is image based. As with many other areas of medicine, the COVID-19 pandemic accelerated adoption.

Delivering medication in the suprachoroidal space would be less invasive than intravitreal injections used to deliver many eye treatments.

Private equity (PE) can bring capital investment to retina specialty practices and significantly increase the incomes of the physicians, said a proponent during a debate on private equity at the AAO meeting. The retina specialist arguing against PE said physicians lose control of their practices and the loyalty of their staff and that profits get prioritized over patients.

Suber S. Huang, M.D., MBA, a panelist for a session about late-breaking research, said the presentation about Syfovre complications among patients treated at the Wolfe Eye Clinic in Iowa is one of the most important of this year's annual meeting. Five patients experienced complications from the new drug for geographic atrophy.

Results at 96 weeks were similar to those at 48 weeks. The FDA approved the 8-mg formulation of Eylea (aflibercept) in August 2023.

Results of this prospective cohort study fits with other evidence showing no association between COVID-19 vaccination and miscarriage.

About 1,700 hospitals will receive lump sums after the Supreme Court ruled that CMS was wrong when it cut reimbursement rates for Part B drugs.

Nemolizumab quelled the itching caused by prurigo nodularis, a rare skin condition. By inhibiting interleukin-31, the experimental drug seems to have a downstream effect on other interleukins secreted during type 2 inflammation.

A subgroup analysis of real-world patient survey data found Black/African American patients with moderate to severe atopic dermatitis had improved disease control, symptoms and treatment satisfaction on Dupixent.

Delgocitinib is first-in-class pan-Janus kinase inhibitor

The announcement has triggered a wave of concerns among users of eye-care products, particularly in those designed to alleviate dry and irritated eyes.

Data from the study revealed that about half of the patients did not receive any treatment during their 12-month follow-up.

Recent data found that extreme heat is projected to lead to a significantly higher burden of excess cardiovascular deaths in the United States by midcentury (2036–2065), with elderly adults and non-Hispanic Black adults being most affected.

Per member spending in private insurance is expected to grow at 6.8% annually due to both utilization and increases in price.

Many carriers reported feelings of concern, anxiousness, and guilt for passing the X-linked inherited retinal disease to their children—and 78% of respondents in a new study believe that carriers should have access to gene therapy options.